3.04
+10.55%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adocia
Its shares trade on Euronext Paris under the ticker ADOC.PA. It has been listed since 20 February 2012. In the fiscal year to 31 December 2025, it reported revenue of €1.5m and a net loss of €16.6m. At that date it held total assets of €28.5m and shareholders' equity of €1.5m.
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Feb 2012
- Employees
- 138
- Website
- adocia.com ↗
Leadership
Pay as last reported
- Dr. Gerard SoulaExecutive Chairman of the Board, since 2011€166,494
- Dr. Olivier SoulaChief Executive Officer, R&D Director, Vice President, Member of the Executive Committee, Director, since 2023€300,001
- Mr. Mathieu-William GilbertChief Financial Officer, Chief Operating Officer
- Mr. Stephane BoisselIndependent Director€49,000
- Mr. Mads DallIndependent Director€42,000
- Ms. Valerie MoumdjianIndependent Director
- Ms. Ekaterina SmirnyaginaIndependent Director, since 2013€49,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Adocia SA has built a strong reputation in the healthcare industry, known for its expertise in developing innovative drug formulation technologies.
- Extensive Intellectual Property: The company holds a significant portfolio of patents and intellectual property rights, which provide a competitive advantage and barriers to entry for competitors.
- Strong R&D Capabilities: Adocia invests heavily in research and development, allowing them to continue developing advanced drug delivery technologies and expand their product pipeline.
Weaknesses
- Dependence on Partnerships: Adocia relies heavily on collaborations with pharmaceutical companies for the development and commercialization of its products, which can lead to limitations in control and potential revenue sharing.
- Limited Market Presence: Although Adocia has gained recognition in the healthcare industry, the company's market penetration and brand visibility are still relatively low compared to its larger competitors.
- Financial Dependency: Adocia's ability to fund its operations and continue its R&D activities heavily relies on securing investments and partnerships, making the company susceptible to financial risks.
Opportunities
- Growing Demand for Innovative Drug Delivery: The increasing need for effective and patient-friendly drug delivery systems presents a significant opportunity for Adocia to capitalize on its technological capabilities.
- Expansion into New Markets: Adocia can explore untapped markets, both geographically and in different therapeutic areas, to diversify its revenue streams and reduce dependency on specific partnerships.
- Strategic Partnerships: Collaborating with established pharmaceutical companies can provide Adocia access to additional resources, expertise, and distribution channels, enhancing its market presence and revenue potential.
Threats
- Intense Competition: Adocia operates in a highly competitive industry with numerous pharmaceutical companies offering similar drug delivery technologies, which can pose challenges in capturing market share.
- Regulatory and Approval Risks: The drug development process is subject to strict regulatory requirements and approval processes, posing potential delays and uncertainties for Adocia's product development timelines.
- Economic Factors: Adocia's financial performance and market prospects are influenced by macroeconomic factors, including changes in healthcare policies, reimbursement systems, and economic downturns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.